Idexx Laboratories, Inc.

Idexx Laboratories, Inc.

IDXX

Get informed when a big investor buys or sells

+ Follow
Market Cap$44.34B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Idexx Laboratories, Inc.Idexx Laboratories, Inc.41.1-70%9.80.7

Earnings Call Q1 2026

May 5, 2026 - AI Summary

Strong Q1 performance + continued diagnostics-led momentum (good/surprising) - Revenue: +14% reported / +11% organic in Q1 2026. - CAG Diagnostics recurring revenue: +11% organic (incl. ~4% net price realization and ~50 bps benefit from equivalent days). - Diagnostics utilization expanding: even with softness in wellness, IDEXX is seeing higher diagnostic frequency/utilization per visit, supporting the care model and volumes. - EPS: $3.47 in Q1; +15% comparable EPS growth. - Margins/ops: Comparable operating margin +100 bps, driven by gross margin expansion and strong recurring revenue.
Full-year guidance raised (good) - Revenue outlook (reported): $4.675B to $4.76B (midpoint implies ~8.6% to 10.6% reported growth). - Organic revenue outlook: +7.7% to +9.7% (midpoint ~70 bps higher than prior guidance). - CAG Diagnostics recurring (organic): +8.7% to +10.7%. - EPS outlook: $14.45 to $14.90 (midpoint +$0.13 vs prior guide), including a $0.05 negative impact from a Q1 equity investment loss.
Clinical visit softness is real, but being “offset” by mix/quality (bad but manageable) - U.S. same-store clinical visits: ~−1% in Q1 (slightly better than initial expectations); wellness visits: −3% while non-well visits: +20 bps YoY. - Management notes aging pets (5+ years) continue to provide green shoots—now the multi-quarter trend supports a more stable outlook. - Updated full-year U.S. clinical visit assumption: ~−1.5% (after Q1 improving trend).

Exclusive for Stockcircle Pro members

Sign upSign Up
$640.00

Target Price by Analysts

18.2% upsideIdexx Laboratories Target Price DetailsTarget Price
$160.46

Current Fair Value

70.4% downside

Overvalued by 70.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$44.34 Billion
Enterprise Value$45.25 Billion
Dividend Yield$- (-)
Earnings per Share$13.17
Beta1.54
Outstanding Shares80,096,000

Return

Return on Equity70.38%ROE
Return on Assets32.35%
Return on Invested Capital67.48%

Valuation & Multiples

P/E Ratio41.11P/E Ratio
PEG278.89PEG
Price to Sales9.84Price to Sales
Price to Book Ratio28.49Price to Book Ratio
Enterprise Value to Revenue10.18
Enterprise Value to EBIT32.16
Enterprise Value to Net Income41
Total Debt to Enterprise0.02
Debt to Equity0.72Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 7, 2026
EPS Estimate
$3.44
Average shareholder expectation
Revenue Estimate
$1.12 B
Average shareholder expectation

Next Earnings Call

Expected Date
August 3, 2026
EPS Estimate
$3.95
Average shareholder expectation
Revenue Estimate
$1.20 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.6022▼ 15.18%
Total Calls123,000▼ 19.40%
Total Puts74,066▼ 35.62%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %89.36%▼ 11.31%
Total Invested$40.22B▼ 18.04%
Investors Holding1,332▼ 75.00%

ESG Score

No data

About Idexx Laboratories, Inc.

CEO: Jonathan Jay Mazelsky

Relevant Senate Committees

Joint Committee on Taxation

This committee directly influences the specifics of tax legislation, including corporate tax structures and capital investment credits, which have a significant and direct impact on Idexx Laboratories' financial performance and investment decisions.

Finance

This committee controls taxation and trade policy, which are fundamental to Idexx Laboratories' profitability, global supply chain, and international sales strategies as a multinational company.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA, which oversees animal health products and devices, and influences labor laws, both of which profoundly impact Idexx Laboratories' operations, product approvals, and costs.